Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Inhaler Technique in Elderly Patients: Impact on Disease Exacerbations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03449316
Recruitment Status : Not yet recruiting
First Posted : February 28, 2018
Last Update Posted : February 28, 2018
Sponsor:
Information provided by (Responsible Party):
Tiago Maricoto, Aveiro-Aradas Family Health Unit

Brief Summary:

Introduction COPD and Asthma affect more than 10% of the population. Most patients use their inhaler incorrectly, mainly the elderly, thereby becoming more susceptible to poor clinical control and exacerbations. Placebo device training is regarded as one of the best teaching methods, but there is scarce evidence to support it as the most effective one to improve major clinical outcomes. Our objective is to perform a single-blinded RCT to assess the impact of this education tool in these patients.

Methods and Analysis A multicentre single-blinded RCT will be set, comparing a placebo-device training programme versus usual care, with a one-year follow-up, in elderly patients with Asthma or COPD. Intervention will be provided at baseline, and after 3 and 6 months, with interim analysis at an intermediate time point. Exacerbation rates were set as primary outcomes, and quality of life, adherence rates, clinical control and respiratory function were chosen as secondary outcomes. A sample size of 146 participants (73 in each arm) was estimated as adequate to detect a 50% reduction in event rates. Two-sample proportions Chi-squared test will be used to study primary outcome and subgroup analysis will be carried out according to major baseline characteristics.

Discussion The investigators expect to confirm that inhaler performance education will significantly reduce exacerbation rate and improve clinical and functional control.

Ethics and dissemination:

Every participant will sign a consent form. A Data Safety Monitoring Board will be set up to evaluate data throughout the study and to monitor stop earlier criteria. Identity of all participants will be protected. Results will be presented in scientific meeting and published in peer-reviewed journals.


Condition or disease Intervention/treatment Phase
Asthma COPD Behavioral: Inhaler technique education Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 146 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Two arms single blinded randomised controlled trial with a 1 year follow up
Masking: Single (Outcomes Assessor)
Masking Description: Blinding for the investigator that acess outcomes, that will not be involved in the intervention process.
Primary Purpose: Treatment
Official Title: Inhaler Technique Education in Elderly Patients With Asthma or COPD: Impact on Disease Exacerbations - a Protocol for a Single-blinded Randomised Controlled Trial
Estimated Study Start Date : June 1, 2018
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: Inhaler technique education
This group will receive a structured and regular follow-up plan, with education on inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of the inhaler technique using placebo devices similar to their own devices. A teach-to-goal approach will be used, repeating all correct steps as many times as needed in order for patients to perform them correctly at each evaluation. There will be visits at baseline and after 3, 6 and 12 months to assess outcomes. In each visit, and prior to the main intervention with the primary investigator, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator.
Behavioral: Inhaler technique education
Teaching of inhalers use with placebo devices in real training

No Intervention: Usual Care

This group will receive usual care from their own Family doctors, with no specific intervention. Each doctor will perform the necessary consultations according to his real life judgment. Besides this, this group will perform visits at baseline and after 3, 6 and 12 months to assess secondary outcomes. At each visit, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to teach inhaler technique, that will be recorded.

If any adjustments are made in drug classes or device types in every participants, this information will be recorded.




Primary Outcome Measures :
  1. Adverse events [ Time Frame: Evaluation at 12 months. ]

    This outcome will be quantifyed as "time to event"

    For Asthma, an event will be defined as increased respiratory clinical symptoms leading the patient to search for medical care, and resulting in any of the following:

    • Need for increased inhaled corticosteroid dose of at least 4x the regular dose
    • Need for increase of short-acting β2 agonists on a daily basis
    • Need for oral corticosteroids
    • Need for oral antibiotics
    • Hospitalization or Emergency Room (ER) visit with increased respiratory clinical symptoms.

    For COPD, an event will be defined as increased respiratory clinical symptoms inducing the patient to search for medical care, and resulting in any of the following:

    • Need for increase of long-acting β2 agonists on a daily basis
    • Need for oral corticosteroids
    • Need for oral antibiotics
    • Hospitalization or ER visit with increased respiratory clinical symptoms. Respiratory-related mortality and all-cause mortality will also be considered an adverse event.


Secondary Outcome Measures :
  1. Clinical assessment [ Time Frame: Evaluation at 12 months ]
    COPD Assessment Tools (CAT) [scale from 0 (worst) to 40 (best) points]

  2. Clinical assessment [ Time Frame: Evaluation at 12 months ]
    modified Medical Research Council (mMRC) [scale from 0 (best) to 4 (worst) points]

  3. Clinical assessment [ Time Frame: Evaluation at 12 months ]
    Control of Allergic Rhinitis and Asthma Test (CARAT) [scale from 0 (worst) to 30 (best) points]

  4. Clinical assessment [ Time Frame: Evaluation at 12 months ]
    Asthma Control Test (ACT) [scale from 5 (worst) to 25 (best) points]

  5. Quality of Life [ Time Frame: Evaluation at 12 months. ]
    Asthma Quality of Life Questionnaire (AQLQ) [scale from 32 (worst) to 224 (best) points]

  6. Quality of Life [ Time Frame: Evaluation at 12 months. ]
    St. George's Respiratory Questionnaire [scale from 0 (best) to 75 (worst) points]

  7. Quality of Life [ Time Frame: Evaluation at 12 months. ]
    Clinical COPD Questionnaire (CCQ) [scale from 0 (best) to 60 (worst) points]

  8. Functional control [ Time Frame: Evaluation at 12 months. ]
    Functional control using FEV1 in liters.

  9. Functional control [ Time Frame: Evaluation at 12 months. ]
    Functional control using FVC in liters.

  10. Functional control [ Time Frame: Evaluation at 12 months. ]
    Functional control using PEF in liters/sec.

  11. Functional control [ Time Frame: Evaluation at 12 months. ]
    Functional control using MEF25-75, in % of predicted values.

  12. Functional control [ Time Frame: Evaluation at 12 months. ]
    Functional control using FEV1/FVC ratio.

  13. Adherence rate [ Time Frame: Evaluation at 12 months. ]
    Adherence rate using the Brief Medication Questionnaire [scale from 0 (best) to 11 (worst) points]

  14. Inhaler technique performance [ Time Frame: Evaluation at 12 months. ]
    Number of errors in inhaler technique (that will be standardized to a score up to 100% scale) [To evaluate inhaler technique performance with each device, the Aerosol Drug Management Improvement Team (ADMIT) protocols and guidelines will be used, evaluating all the recommended steps for inhaler use on each one of them. For those devices that do not have any protocol from the ADMIT group, investigators will use the recommendations from the manufacture`s Summary of Product Characteristics.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 130 Years   (Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Elderly patients
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with a diagnosis of COPD or Asthma, medicated with any kind of inhaler device (pressurized Metered Dose Inhaler (pMDI) with or without Spacer, Dry Powder Inhaler (DPI) or Soft Mist), aged ≥65 years and being a regular user of primary health care services (defined as having at least one consultation performed in the last two years with his/her own Family Doctor). In order to minimize diagnostic inaccuracy, Asthma and COPD diagnosis will be reviewed in every participant at baseline prior to enrolment and according to GINA and GOLD strategies.

Exclusion Criteria:

  • Severe or acute illness (such as unstable cardiovascular status, unstable angina, recent myocardial infarction (within one month) or pulmonary embolism, haemoptysis of unknown origin, recent pneumothorax (within one month), recent thoracic, abdominal or eye surgery (within one month), acute nausea or vomiting, severe respiratory distress, dementia). Patients with intermittent asthma, as well as COPD patients with mild obstruction (GOLD class I) will be excluded, since these patients do not need to take inhaler medication on a daily basis, and tend to have a low frequency of disease exacerbations.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Tiago Maricoto, Principal Investigator, Aveiro-Aradas Family Health Unit
ClinicalTrials.gov Identifier: NCT03449316     History of Changes
Other Study ID Numbers: Protocol V3
First Posted: February 28, 2018    Key Record Dates
Last Update Posted: February 28, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: All data from the trial will be kept in a safe place of the principal investigator`s institutional facilities and by the Data Safety Monitoring Board, in accordance with the national and international clinical research policies.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Tiago Maricoto, Aveiro-Aradas Family Health Unit:
Nebulizers and Vaporizers

Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Lung Diseases, Obstructive
Lung Diseases
Disease Progression
Bronchial Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Disease Attributes
Pathologic Processes